Evidence map›Paper›PMID 33968133›Full record

ArticleFrontiers in genetics2021

Gene Targeting in Disease Networks.

Deborah Weighill, Marouen Ben Guebila, Kimberly Glass, John Platig, Jen Jen Yeh, John Quackenbush

Abstract read
In one paragraph

Article in Frontiers in genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Deborah WeighillDepartment of Biostatistics, Harvard T. H. Chan School of Public Health, Harvard University, Boston, MA, United States.
Marouen Ben GuebilaDepartment of Biostatistics, Harvard T. H. Chan School of Public Health, Harvard University, Boston, MA, United States.
Kimberly GlassDepartment of Biostatistics, Harvard T. H. Chan School of Public Health, Harvard University, Boston, MA, United States.
John PlatigChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, United States.
Jen Jen YehDepartments of Surgery and Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
John QuackenbushDepartment of Biostatistics, Harvard T. H. Chan School of Public Health, Harvard University, Boston, MA, United States.

Funding

Unraveling the Complexities of Risk and Mechanism in CancerR35CA220523 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI QUACKENBUSH, JOHN · 2018 to 2024
$6.0M
Tumor Subtypes and Therapy Response in Pancreatic CancerR01CA199064 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TSAI, SUSAN, YEH, JEN JEN · 2016 to 2021
$4.4M
WebMeV: A Robust Platform for Intuitive Genomic Data AnalysisU24CA231846 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI QUACKENBUSH, JOHN · 2019 to 2023
$3.2M
Using Integrative Networks to Explore Heterogeneous Phenotypes in COPDK25HL133599 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GLASS, KIMBERLY RENEE · 2016 to 2020
$945k
Context matters: Network modeling of COPD regulatory variants across tissues and exposuresK25HL140186 · NHLBI · UNIVERSITY OF VIRGINIA · PI PLATIG, JOHN · 2018 to 2022
$926k
NCI NIH HHS R01 CA199064NCI NIH HHS R35 CA220523NCI NIH HHS U24 CA231846NHLBI NIH HHS K25 HL133599NHLBI NIH HHS K25 HL140186
6 · The paper itself

Abstract

Profiling of whole transcriptomes has become a cornerstone of molecular biology and an invaluable tool for the characterization of clinical phenotypes and the identification of disease subtypes. Analyses of these data are becoming ever more sophisticated as we move beyond simple comparisons to consider networks of higher-order interactions and associations. Gene regulatory networks (GRNs) model the regulatory relationships of transcription factors and genes and have allowed the identification of differentially regulated processes in disease systems. In this perspective, we discuss gene targeting scores, which measure changes in inferred regulatory network interactions, and their use in identifying disease-relevant processes. In addition, we present an example analysis for pancreatic ductal adenocarcinoma (PDAC), demonstrating the power of gene targeting scores to identify differential processes between complex phenotypes, processes that would have been missed by only performing differential expression analysis. This example demonstrates that gene targeting scores are an invaluable addition to gene expression analysis in the characterization of diseases and other complex phenotypes.

Indexed as

cancer genomicsdifferential targetinggene regulatory networksgene targetingnetwork medicine

Identifiers

PMID33968133
PMCPMC8103030

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.